The antibiotic clofoctol suppresses glioma stem cell proliferation by activating KLF13

Area of Science:

• Neuro-oncology
• Cancer Biology
• Drug Discovery

Background:

• Gliomas are aggressive brain tumors with poor patient prognosis despite extensive treatment.
• Glioma stem cells (GSCs) are implicated in therapeutic resistance and tumor recurrence, driving poor outcomes.
• Targeting GSCs presents a promising strategy for improving glioma treatment efficacy.

Purpose of the Study:

• To identify novel therapeutic agents targeting GSCs.
• To elucidate the mechanism of action for potential anti-glioma drugs.
• To evaluate the efficacy of identified compounds in preclinical glioma models.

Main Methods:

• High-throughput drug screening using GSCs as a cellular model.
• In vitro assays assessing colony formation and apoptosis induction in GSCs.
• In vivo efficacy studies using patient-derived xenografts (PDXs) and transgenic glioma models.
• Mechanistic studies involving gene expression analysis and protein-binding assays.

Main Results:

• Clofoctol was identified as a potent inhibitor of GSCs, reducing colony formation and inducing apoptosis.
• Clofoctol treatment significantly suppressed tumor growth in vivo, particularly in PDX and transgenic models.
• The mechanism involves clofoctol upregulating the tumor suppressor Kruppel-like factor 13 (KLF13) via binding to the RNA-binding protein Upstream of N-ras (UNR).

Conclusions:

• Clofoctol demonstrates significant therapeutic potential for treating gliomas by targeting GSCs.
• Upregulation of KLF13, mediated by UNR, is a key mechanism for clofoctol's anti-glioma activity.
• UNR represents a novel drug target for developing future glioma therapies.